Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
680 participants
INTERVENTIONAL
2011-09-01
2013-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SYR-472 group
(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
SYR-472
oral, for up to 52 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SYR-472
oral, for up to 52 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
3. Diabetes Mellitus
Exclusion Criteria
2. The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Senior Director
Role: STUDY_DIRECTOR
Takeda (Note: This product was divested to Teijin Pharma Limited in 2023)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akita, Akita, Japan
Kisarazu-shi, Chiba, Japan
Fukuoka, Fukuoka, Japan
Munakata-shi, Fukuoka, Japan
Koriyama-shi, Fukushima, Japan
Gihu-shi, Gihu, Japan
Fukuyama-shi, Hiroshima, Japan
Hiroshima, Hiroshima, Japan
Eniwa-shi, Hokkaido, Japan
Ishikari-shi, Hokkaido, Japan
Nakagawa-gun, Hokkaido, Japan
Obihiro-shi, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Kobe, Hyōgo, Japan
Mito, Ibaragi, Japan
Naka, Ibaragi, Japan
Takamatsu, Kagawa-ken, Japan
Sagamihara-shi, Kanagawa, Japan
Yokohama, Kanagawa, Japan
Kumamoto, Kumamoto, Japan
Tamana-shi, Kumamoto, Japan
Kyoto, Kyoto, Japan
Nagano, Nagano, Japan
Nagawaki-shi, Nagasaki, Japan
Ōita, Oita Prefecture, Japan
Minoh, Osaka, Japan
Osaka, Osaka, Japan
Sakai-shi, Osaka, Japan
Ageo-shi, Saitama, Japan
Kawaguchi-shi, Saitama, Japan
Koshigaya-shi, Saitama, Japan
Kuki-shi, Saitama, Japan
Saitama-shi, Saitama, Japan
Suntou-gun, Shizuoka, Japan
Oyama-shi, Tochigi, Japan
Chuo-ku, Tokyo, Japan
Koganei-shi, Tokyo, Japan
Meguro-ku, Tokyo, Japan
Shibuya-ku, Tokyo, Japan
Tama-shi, Tokyo, Japan
Tiyoda-ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JapicCTI-111592
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1123-6415
Identifier Type: REGISTRY
Identifier Source: secondary_id
SYR-472/OCT-001
Identifier Type: -
Identifier Source: org_study_id